title: Treatment of kaposiform hemangioendothelioma and tufted angioma.
abstract: This meta-analysis was to evaluate the efficacy of current treatment modalities for kaposiform hemangioendothelioma and tufted angioma. A systematic review was performed using PubMed (Medline), Web of Science and Embase for clinical studies. The outcome was measured by pooled response rate with 95% confidence intervals (CIs), together with heterogeneity, subgroup analysis, sensitivity analysis and publication bias. Fifteen studies with 244 participants were included in this analysis. Vincristine therapy exhibited a relatively higher response rate (0.72; 95%CI, 0.64-0.79) compared with other therapies including systemic corticosteroid (0.27; 95%CI, 0.17-0.36), interferon (0.36; 95%CI, 0.24-0.48), radiotherapy (0.49; 95%CI, 0.26-0.73), embolization (0.66; 95%CI, 0.48-0.83), aspirin/ticlopidine (0.42; 95%CI, 0.06-0.78) and sirolimus (0.57; 95%CI, 0.00-0.10), in treating KHE/TA. Subgroup analysis indicated that the efficacy of systemic corticosteroids therapy was age-related. The pooled response rate was 0.15 (95%CI, 0.08-0.23) for participants 3.5 months of age and older compared with 0.35 (95% CI, 0.26-0.44) for participants less than 3.5 months. Regarding side effects, systemic corticosteroids treatment was 0.32 (95%CI, 0.15-0.50), vincristine modality was 0.16 (95%CI, 0.08-0.24) and interferon therapy was 0.28 (95%CI, 0.13-0.43). In conclusion, as one of the first reviews evaluating the effect of common therapies in the treatment of KHE/TA, our meta-analysis displayed that vincristine was more effective. Thus, vincristine was the most effective, providing evidence supporting the use of vincristine as a first-line therapy for KHE/TA.
authors.affiliation: College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.|Department of Oral Surgery and Department of Oral-Maxillofacial Head and Neck Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China.
authors.forename: Xiao Han
authors.initials: XH
authors.lastname: Liu
authors.affiliation: Jining Medical University, Shandong, China.
authors.forename: Jia Ying
authors.initials: JY
authors.lastname: Li
authors.affiliation: Key Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Xin Hua
authors.initials: XH
authors.lastname: Qu
authors.affiliation: Pudong Institute of Preventive Medicine, Fudan University, Shanghai, China.
authors.forename: Wei Li
authors.initials: WL
authors.lastname: Yan
authors.affiliation: Department of Oral Surgery and Department of Oral-Maxillofacial Head and Neck Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Oral Surgery and Department of Oral-Maxillofacial Head and Neck Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China.
authors.forename: Chi
authors.initials: C
authors.lastname: Yang
authors.affiliation: College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.|Department of Oral Surgery and Department of Oral-Maxillofacial Head and Neck Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China.
authors.forename: Jia Wei
authors.initials: JW
authors.lastname: Zheng
mesh_terms: D002986:Clinical Trials as Topic; D006390:Hemangioendothelioma / Q000188:drug therapy / Q000628:therapy*; D006391:Hemangioma / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D059885:Kasabach-Merritt Syndrome / Q000188:drug therapy / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000628:therapy*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine
keywords: Kasabach-Merritt phenomenon; kaposiform hemangioendothelioma; treatment; tufted angioma